Mazen Noureddin - Concepedia

Author

Mazen Noureddin

Also Known As

L. Nikoleishvili, M Noureddin, M. Imadeddin NOUREDDIN, M. Noureddin, Mauro Viganò, Mazen Noureddin, N Alkhouri, Noureddin, M., Noureddin, Mazen, Shelly Lu

538

Publications

20.1K

Citations

H-Index

139

Concepts

All Affiliations

Cedars-Sinai Medical Center University of California San Diego National University Health System Virginia Commonwealth University Houston Methodist

About

Mazen Noureddin is an author at Cedars-Sinai Medical Center specializing in medicine, hepatology, and liver physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	39	3.7K
2	Health Sciences	14	15	1.1K
3	Natural Sciences	2	2	77
4	Business	1	1	124
5	Engineering	1	1	13

Mazen Noureddin

145

Publications

13.3K

Citations

H-Index

Page 1

	Year	Citations
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis Stephen A. Harrison, Pierre Bédossa, Cynthia D. Guy, New England Journal of Medicine	2024	1.4K
The global burden of metabolic disease: Data from 2000 to 2019 Nicholas Chew, Cheng Han Ng, Darren Jun Hao Tan, Cell Metabolism ObesityMetabolic SyndromeGlobal BurdenEpidemiologyMetabolic Disorder	2023	668
NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances Mazen Noureddin, Aarshi Vipani, Catherine Bresee, The American Journal of Gastroenterology	2018	561
Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials Mazen Noureddin, Jessica Lam, Michael R. Peterson, Hepatology	2013	536
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis Arun J. Sanyal, Pierre Bédossa, Mandy Fraessdorf, New England Journal of Medicine	2024	346
Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial Samer Gawrieh, Mazen Noureddin, Nicole Loo, Hepatology	2021	335
Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial) Rohit Loomba, Claude B. Sirlin, Brandon Ang, Hepatology	2014	333
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease Rohit Loomba, Zeid Kayali, Mazen Noureddin, Gastroenterology ObesityMetabolic SyndromeMetabolic Associated SteatohepatitisHepatologyMetabolic Associated Steatotic Liver Disease	2018	329
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension Naga Chalasani, Manal F. Abdelmalek, Guadalupe García–Tsao, Gastroenterology	2019	326
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial Keyur Patel, Stephen A. Harrison, Magdy Elkhashab, Hepatology	2020	311

Page 1